Cargando…

Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population

BACKGROUND: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this...

Descripción completa

Detalles Bibliográficos
Autores principales: Benekli, Mustafa, Yalcin, Suayib, Ozkan, Metin, Elkiran, Emin Tamer, Sevinc, Alper, Cabuk, Devrim, Coskun, Hasan Senol, Oksuzoglu, Berna, Bayar, Banu, Akbulat, Akif, Ozet, Ahmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271783/
https://www.ncbi.nlm.nih.gov/pubmed/25548522
http://dx.doi.org/10.2147/OTT.S70670
_version_ 1782349670638419968
author Benekli, Mustafa
Yalcin, Suayib
Ozkan, Metin
Elkiran, Emin Tamer
Sevinc, Alper
Cabuk, Devrim
Coskun, Hasan Senol
Oksuzoglu, Berna
Bayar, Banu
Akbulat, Akif
Ozet, Ahmet
author_facet Benekli, Mustafa
Yalcin, Suayib
Ozkan, Metin
Elkiran, Emin Tamer
Sevinc, Alper
Cabuk, Devrim
Coskun, Hasan Senol
Oksuzoglu, Berna
Bayar, Banu
Akbulat, Akif
Ozet, Ahmet
author_sort Benekli, Mustafa
collection PubMed
description BACKGROUND: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication. PATIENTS AND METHODS: Patients with advanced DTC and MTC were retrospectively identified from the Turkish Ministry of Health database. Data on these patients were prospectively collected before permission is granted to use sorafenib. RESULTS: Thirty patients with complete data were analyzed: 14 DTC (papillary number [n] =10; follicular n=4) and 16 MTC. The median age of the patients was 57 years (range: 28–79 years), and there were 18 males and 12 females. All DTC patients were iodine refractory and had received a median three doses of radioactive iodine (range: 1–7 doses). Sorafenib was used for a median of 12 months (range: 1–49 months). The overall response rate was 20%, all partial responses, with no complete response. The overall response rate was 14% in DTC and 25% in MTC patients. The median progression-free survival (PFS) was 17.1 months (95% confidence interval [CI]: 7.3–26.8) and overall survival (OS) was not reached. The 2-year PFS and OS were 39% and 68%, respectively. DTC and MTC patients had similar survival outcomes: median PFS of 21.3 months (95% CI: 5.8–36.7) versus 14.5 months (95% CI: 3.7–25.2), respectively (P=0.36), with the median OS not reached in either group (P=0.17). Tumor marker levels did not have any prognostic or predictive role. The toxicity profile was similar to that of other sorafenib trials. CONCLUSION: Sorafenib is an effective and well-tolerated treatment in advanced thyroid cancers.
format Online
Article
Text
id pubmed-4271783
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-42717832014-12-29 Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population Benekli, Mustafa Yalcin, Suayib Ozkan, Metin Elkiran, Emin Tamer Sevinc, Alper Cabuk, Devrim Coskun, Hasan Senol Oksuzoglu, Berna Bayar, Banu Akbulat, Akif Ozet, Ahmet Onco Targets Ther Original Research BACKGROUND: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib is used in Turkey with special permission by the Ministry of Health for this indication. PATIENTS AND METHODS: Patients with advanced DTC and MTC were retrospectively identified from the Turkish Ministry of Health database. Data on these patients were prospectively collected before permission is granted to use sorafenib. RESULTS: Thirty patients with complete data were analyzed: 14 DTC (papillary number [n] =10; follicular n=4) and 16 MTC. The median age of the patients was 57 years (range: 28–79 years), and there were 18 males and 12 females. All DTC patients were iodine refractory and had received a median three doses of radioactive iodine (range: 1–7 doses). Sorafenib was used for a median of 12 months (range: 1–49 months). The overall response rate was 20%, all partial responses, with no complete response. The overall response rate was 14% in DTC and 25% in MTC patients. The median progression-free survival (PFS) was 17.1 months (95% confidence interval [CI]: 7.3–26.8) and overall survival (OS) was not reached. The 2-year PFS and OS were 39% and 68%, respectively. DTC and MTC patients had similar survival outcomes: median PFS of 21.3 months (95% CI: 5.8–36.7) versus 14.5 months (95% CI: 3.7–25.2), respectively (P=0.36), with the median OS not reached in either group (P=0.17). Tumor marker levels did not have any prognostic or predictive role. The toxicity profile was similar to that of other sorafenib trials. CONCLUSION: Sorafenib is an effective and well-tolerated treatment in advanced thyroid cancers. Dove Medical Press 2014-12-15 /pmc/articles/PMC4271783/ /pubmed/25548522 http://dx.doi.org/10.2147/OTT.S70670 Text en © 2015 Benekli et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Benekli, Mustafa
Yalcin, Suayib
Ozkan, Metin
Elkiran, Emin Tamer
Sevinc, Alper
Cabuk, Devrim
Coskun, Hasan Senol
Oksuzoglu, Berna
Bayar, Banu
Akbulat, Akif
Ozet, Ahmet
Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population
title Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population
title_full Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population
title_fullStr Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population
title_full_unstemmed Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population
title_short Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population
title_sort efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a turkish population
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271783/
https://www.ncbi.nlm.nih.gov/pubmed/25548522
http://dx.doi.org/10.2147/OTT.S70670
work_keys_str_mv AT beneklimustafa efficacyofsorafenibinadvanceddifferentiatedandmedullarythyroidcancerexperienceinaturkishpopulation
AT yalcinsuayib efficacyofsorafenibinadvanceddifferentiatedandmedullarythyroidcancerexperienceinaturkishpopulation
AT ozkanmetin efficacyofsorafenibinadvanceddifferentiatedandmedullarythyroidcancerexperienceinaturkishpopulation
AT elkiranemintamer efficacyofsorafenibinadvanceddifferentiatedandmedullarythyroidcancerexperienceinaturkishpopulation
AT sevincalper efficacyofsorafenibinadvanceddifferentiatedandmedullarythyroidcancerexperienceinaturkishpopulation
AT cabukdevrim efficacyofsorafenibinadvanceddifferentiatedandmedullarythyroidcancerexperienceinaturkishpopulation
AT coskunhasansenol efficacyofsorafenibinadvanceddifferentiatedandmedullarythyroidcancerexperienceinaturkishpopulation
AT oksuzogluberna efficacyofsorafenibinadvanceddifferentiatedandmedullarythyroidcancerexperienceinaturkishpopulation
AT bayarbanu efficacyofsorafenibinadvanceddifferentiatedandmedullarythyroidcancerexperienceinaturkishpopulation
AT akbulatakif efficacyofsorafenibinadvanceddifferentiatedandmedullarythyroidcancerexperienceinaturkishpopulation
AT ozetahmet efficacyofsorafenibinadvanceddifferentiatedandmedullarythyroidcancerexperienceinaturkishpopulation